AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8046475
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of dipyridamole (0.14 mg/kg/min for 4 min, total 0.56 mg/kg)
Trial: 8046475
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of dipyridamole (0.14 mg/kg/min for 6 min, total 0.84 mg/kg)
Trial: 8046475
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of dipyridamole
Trial: 31115462
Drug: Dietary fulvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fulvic acid supplementation (0.6 g kg‐1)
Trial: 31115462
Drug: Dietary fulvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fulvic acid supplementation (1 g kg‐1)
Trial: 31115462
Drug: Dietary fulvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fulvic acid supplementation (0.2 g kg‐1)
Trial: 23412113
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge (4 mg deliverable)
Trial: 21466258
Drug: Probiotic ice-cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic ice-cream containing Bifidobacterium lactis Bb12 and Lactobacillus acidophilus La5
Trial: 21466258
Drug: Control ice-cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control ice-cream (placebo)
Trial: 19884613
Drug: Bupropion plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion plus nicotine lozenge
Trial: 2671414
Drug: Papaverine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (40 mg)
Trial: 2671414
Drug: Papaverine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (20 mg) and Phentolamine (0.5 mg)
Trial: 797539
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg clotrimazole troche, ten times a day
Trial: 797539
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg clotrimazole troche, ten times a day
Trial: 28525632
Drug: Pregabalin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (300 or 450 mg/day, twice daily)
Trial: 27286894
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (DEX implant) only
Trial: 27286894
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (DEX implant) with other RVO treatment
Trial: 27286894
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (DEX implant) with ≥2 DEX implants
Trial: 24674676
Drug: Both sevelamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sevelamer tablet forms
Trial: 15649160
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 11.2 microg.kg(‐1)
Trial: 15649160
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 15 microg.kg(‐1)
Trial: 15649160
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 20 microg.kg(‐1)
Trial: 7720945
Drug: Melatonin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (1 mg at 8:00 and 0.75 mg at 10:00 and 12:00 A.M.)
Trial: 1974484
Drug: Arginine (ARG)
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine (ARG) 0.5 g/kg infused i.v. over 30 min with GHRH 1 microgram/kg i.v.
Trial: 1974484
Drug: Arginine (ARG)
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine (ARG) 0.5 g/kg infused i.v. with Pyridostigmine (PD) 60 mg orally
Trial: 1974484
Drug: Combined PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined PD and GHRH administration
Trial: 7237220
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose droperidol (0.005 mg x kg‐1)
Trial: 28447625
Drug: Dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements (combination pill)
Trial: 21777972
Drug: HSCT (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSCT (200 mg/kg intravenous cyclophosphamide, 6.5 mg/kg intravenous rabbit antithymocyte globulin)
Trial: 21777972
Drug: Cyclophosphamide (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (1.0 g/m² intravenous once per month for 6 months)
Trial: 12536495
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (LMWH) administered by hypodermic injection for four weeks
Trial: 22922591
Drug: CHF5074 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5074 200 mg/d for 14 d
Trial: 22922591
Drug: CHF5074 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5074 400 mg/d for 14 d
Trial: 22922591
Drug: CHF5074 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5074 600 mg/d for 14 d
Trial: 22922591
Drug: CHF5074 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5074 (all doses)
Trial: 8731665
Drug: Topical all‐trans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical all‐trans retinoic acid (0.1%)
Trial: 8731665
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium lauryl sulphate (2%)
Trial: 8731665
Drug: Vehicle creams
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle creams
Trial: 1656739
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg on day 1 followed by 250 mg/day for days 2-5)
Trial: 1656739
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg three times daily for 10 days)
Trial: 30704508
Drug: Early care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early care bundle intervention including early and comprehensive management of symptoms, prompt detection and treatment of precipitating factors, intravenous nitrate boluses, low-dose diuretics, non-invasive ventilation, and preventive low-molecular-weight heparin.
Trial: 28103942
Drug: Fluralaner topical
RxNorm normalized name: fluralaner Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluralaner topical solution
Trial: 26009229
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (control)
Trial: 23403682
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (14-day lansoprazole, amoxicillin, and clarithromycin)
Trial: 23403682
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole)
Trial: 23403682
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Trial: 23403682
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with 14-day bismuth-based quadruple therapy
Trial: 23403682
Drug: Nonadherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadherence to initial therapy
Trial: 23403682
Drug: Single-treatment course
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-treatment course analysis
Trial: 22111592
Drug: Daily mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mixed nutritional supplement (SUP, ∼5.1 MJ·d⁻¹)
Trial: 17946394
Drug: Simulation model
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulation model of glucose-insulin system
Trial: 17946394
Drug: Open-loop insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-loop insulin infusion strategy
Trial: 17946394
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin infusion strategy
Trial: 11511139
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone
Trial: 264798
Drug: Cyclophosphamide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide therapy
Trial: 11511139
Drug: Methylprednisolone therapy
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone therapy
Trial: 3427807
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% solution applied once daily for 1 day
Trial: 3427807
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% solution applied once daily for 2 days (day one and day three)
Trial: 3427807
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% solution applied once daily for 3 days (day one, day three and day six)
Trial: 30040057
Drug: Drug-eluting balloon
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting balloon (DEB) percutaneous transluminal angioplasty (PTA)
Trial: 23558673
Drug: IMRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT with XELOX chemotherapy
Trial: 23558673
Drug: 3D-CRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D-CRT with 5-FU/FA chemotherapy
Trial: 20504298
Drug: Ibuprofen 3
RxNorm normalized name: ibuprofen 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 3 x 400 mg oral for three days
Trial: 20504298
Drug: Ciprofloxacin 2
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 2 x 250 mg (+1 placebo) oral for three days
Trial: 18536783
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (110 microg once daily)
Trial: 1295724
Drug: Levodropropizine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodropropizine (60 mg and 90 mg)
Trial: 1295724
Drug: Dropropizine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dropropizine (60 mg and 90 mg)
Trial: 21050973
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg) plus clopidogrel (75 mg) daily (AC group)
Trial: 21050973
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg) alone daily (A group)
Trial: 15271770
Drug: leflunomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leflunomide (20 mg once daily) plus sulfasalazine (2 g once daily)
Trial: 15271770
Drug: placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus sulfasalazine (2 g once daily)
Trial: 2086492
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks of daily CDM administration
Trial: 30088545
Drug: Intradetrusor onabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intradetrusor onabotulinumtoxinA injections (300U)
Trial: 30088545
Drug: Oral oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxybutynin (5mg, three times/day)
Trial: 25128203
Drug: Matched control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched control group maintaining daily activity levels.
Trial: 16096704
Drug: Gemcitabine 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1250 mg/m2 + vinorelbine 30 mg/m2 (GV group)
Trial: 16096704
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m2 + gemcitabine 1000 mg/m2 + vinorelbine 25 mg/m2 (CGV group)
Trial: 8054254
Drug: Paracetamol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1 g 4 times per day)
Trial: 1612951
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy multiple daily fractionation (MDF), using 3 daily fractions of 1.25 Gy each, up to a total dose of 37.5 Gy in 12 days.
Trial: 1612951
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy conventional fractionation (CF), for a total dose of 50 Gy/5 weeks.
Trial: 1612951
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (cystectomy alone).
Trial: 31570100
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active medication treatment
Trial: 31570100
Drug: General factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General factors affecting treatment retention
Trial: 26526623
Drug: Toremifene 60
RxNorm normalized name: toremifene 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 60 mg plus ADT (TOPADT)
Trial: 23016517
Drug: Androgen-deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen-deprivation therapy (ADT)
Trial: 26526623
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg plus ADT (RAPADT)
Trial: 21399536
Drug: AAKG supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAKG supplementation (3,700 mg arginine alpha-ketoglutarate per serving)
Trial: 18097109
Drug: Short-course intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course intermittent chemotherapy (2EHRZ 3 /4RH 3 ) thrice weekly for 6 months
Trial: 15118032
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate (1.25 mg per twenty-four hours)
Trial: 11986765
Drug: Capecitabine (1255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1255 mg m(‐2) twice daily, days 1-14)
Trial: 11986765
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg m(‐2))
Trial: 9829849
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment initiated until the third year of life (Group 1)
Trial: 9829849
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment initiated at age 5 years and above (Group 2)
Trial: 9829849
Drug: Repeated joint
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated joint bleeding (>5) prior to prophylactic treatment
Trial: 8137517
Drug: Injectable bromocriptine
RxNorm normalized name: bromocriptine Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable bromocriptine 50 mg intramuscularly for 28 days (Group A)
Trial: 8137517
Drug: Oral bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bromocriptine 7.5 mg daily for 28 days (Group B)
Trial: 29225313
Drug: Coffee polyphenols
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee polyphenols (CPPs) 297.8 mg daily for 4 weeks
Trial: 19339127
Drug: Soy Isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy Isoflavones Extract (SIE) 120mg daily
Trial: 17302023
Drug: Pillar(R) Palatal
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pillar(R) Palatal Implant System
Trial: 11376828
Drug: Subcutaneous patch
RxNorm normalized name: Patch
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous patch electrode
Trial: 11376828
Drug: Subcutaneous array
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous array electrode
Trial: 3167526
Drug: Nefopam hydrochloride
RxNorm normalized name: nefopam hydrochloride
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam hydrochloride (20 mg)
Trial: 27894271
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise program involving progressive and challenging balance training and neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week for the first three months, and twice a week at home thereafter, totaling 18 sessions.
Trial: 22462558
Drug: Amlodipine/losartan 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/losartan 5 mg/100 mg combination
Trial: 20569455
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing polyunsaturated fatty acids and Humulus lupulus extract (active group)
Trial: 20569455
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (active group)
Trial: 8624233
Drug: Oral-B 35
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B 35 toothbrush
Trial: 28025309
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) using the Prevena NPWT device
Trial: 22732468
Drug: Therapeutic vaccine
RxNorm normalized name: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic vaccine
Trial: 12894612
Drug: Clonazepam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (4 weeks treatment)
Trial: 12894612
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 weeks treatment)
Trial: 10227808
Drug: Inhaled interleukin-5
RxNorm normalized name: interleukin-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled interleukin-5 (IL-5)
Trial: 8916983
Drug: Add-back hormone
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add-back hormone replacement therapy (HRT) with cyclical oestradiol/norgestrol in combination with Zoladex (goserelin acetate)
Trial: 8916983
Drug: Combined oestrogen/progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oestrogen/progestogen given for 21 months after initial GnRH agonist treatment for 3 months
Trial: 3953351
Drug: Intravenous lorcainide
RxNorm normalized name: lorcainide
DrugBank: Lorcainide (DB13653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lorcainide (LOR) 2 mg/kg then 200 mg/24hr
Trial: 3953351
Drug: Lidocaine (LID)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (LID) 1 mg/kg then 2 mg/min
Trial: 24643636
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid), three times daily for 4 months
Trial: 25119571
Drug: Uzara (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uzara (80 mg/8 hours for two doses, then 40 mg/8 hours)
Trial: 25119571
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg/6 hours)
Trial: 15847356
Drug: Itopride hydrochloride
RxNorm normalized name: Itopride hydrochloride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride hydrochloride 50mg three times daily for two weeks
Trial: 15847356
Drug: Domperidone 10mg
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10mg three times daily for two weeks
Trial: 1909525
Drug: Safety scores
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety scores (pre-inhalation)
Trial: 6623361
Drug: Modified amino
RxNorm normalized name: LYSYL-PEG-LAUROYL-MODIFIED AMINO ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified amino acid solution rich in branched chains and low in aromatic amino acids and methionine (F080)
Trial: 31418598
Drug: C-SSRRMT capsules
RxNorm normalized name: chondroitin sulfates Oral Capsule [Optiflex-C]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-SSRRMT capsules
Trial: 31418598
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release market tablets